Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NB-UVB plus crisaborole for stable non-segmental vitiligo
ChiCTR2500100175Phase 4Not yet recruiting
- Sponsor
- Chongqing Fifth People's Hospital
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of crisaborole in Vitiligo (2 arms), sponsored by Chongqing Fifth People's Hospital. Primary endpoints: Vitiligo Area Scoring Index (VASI) at 12 weeks, Effective rate at 12 weeks and 3 more. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
crisaborole
03
Conditions
Vitiligo
Beyond the preview
Go deeper on ChiCTR2500100175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500100175.